

## Type 2 Diabetes in adults (medicines update) Committee meeting 14 Day 1

**Date:** 23/10/2025

**Location:** Hybrid, NICE London Office

**Minutes:** Final

<b>Committee members present:</b>		
Waqar Shah (Chair)		Present for notes 1 – 6
Chirag Bakhai		Present for notes 1 – 6
Catherine Bewsey		Present for notes 1 – 6
Mimi Chen		Present for notes 1 – 6
Hussain Contractor		Present for notes 1 – 6
Dan Cuthbertson (Topic Adviser)		Present for notes 1 – 6
Anne Dornhorst		Present for notes 1 – 6
Hugh Gallagher		Present for notes 1 – 6
Natasha Jacques		Present for notes 1 – 6
Sallianne Kavanagh		Present for notes 1 – 6
Sharon McCarthy		Present for notes 1 – 6
Soon Song		Present for notes 1 – 6
Annette Swinkels		Present for notes 1 – 6
Dominic Taylor		Present for notes 1 – 6
John Turner		Present for notes 1 – 6

<b>In attendance:</b>		
Astrid Aregui	Senior Guidance Content Designer	Present for notes 1 – 6
Sarah Dwyer	Technical Analyst	Present for notes 1 – 6
James Hawkins	Health Economics Adviser	Present for notes 1 – 6
Sarah Matthews	Technical Analyst	Present for notes 1 – 6
Caroline Mulvihill	Topic Lead	Present for notes 1 – 6
Adam O’Keefe	Project Manager	Present for notes 1 – 6
Muksitur Rahman	Health Economist	Present for notes 1 – 6
Magdalena Watras	Pharmacist Clinical Adviser	Present for notes 1 – 6
Philip Williams	Finance Analyst	Present for notes 1 – 6
George Wood	Senior Technical Analyst	Present for notes 1 – 6

<b>NICE observers:</b>	
Eric Power	Deputy Director, Centre for Guidelines, NICE
Jacoline Bouvy	Programme Director, Medicines Evaluation, NICE
Simon Ellis	Associate Director, Centre for Guidelines, NICE
Charlotte Fairclough	Technical Analyst, Centre for Guidelines, NICE
Lesley Owen	Health Economics Adviser, SEA Directorate, NICE

<b>Apologies:</b>	
Neel Basudev	Committee member
Sithembile Thokozile Chinaire	Committee member
Gosia Wamil	Committee member
Lina Manounah	Technical Analyst, NICE

**1. Welcome, introductions and apologies**

The Chair welcomed the Committee members and attendees to Day one of the fourteenth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, these are noted below:

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Mimi Chen	Committee member, Consultant Diabetologist	Sponsored attendance at European Association of the Study of Diabetes (EASD) conference in Vienna in September 2025 by Eli Lilly for obesity related discussion. Sponsored travel, accommodation and conference fees.	Direct, financial	Declare and participate Not specific to the scope of the guideline update

Hussain Contractor	Committee member, Consultant Cardiologist	Talk at European Society of Cardiology meeting in Madrid about Trust's Post-PCI clinic, funded by Amorim (a lipid company).	Direct, financial	Declare and participate Not specific to the scope of the guideline update
Hussain Contractor	Committee member, Consultant Cardiologist	Attended round table meeting with primary care colleagues about Tirzepatide for weight loss, meeting was sponsored by Eli Lilly	Direct Non-financial, professional and personal	Declare and participate Not specific to the scope of the guideline update
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Attended and spoke at two educational European meetings sponsored by Perspectum. Talks were non-promotional and not related to this guideline update.	Direct financial	Declare and participate Not specific to the scope of the guideline update
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Attended and spoke at European Association of the Study of Diabetes (EASD) conference in Vienna in September 2025, sponsored by Madrigal. Talks were non-promotional and related to diabetes in liver health. Consultancy fees paid to University.	Direct financial Indirect financial (for fees paid to University)	Declare and participate Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Confirmed previous declaration of having presented abstract at the European Association of the Study of Diabetes (EASD) conference in Vienna ion	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update

		September 2025 entitled "C-peptide as an adjunctive diagnostic tool for early identification of young-onset type 2 diabetes". Did not receive any financial support to attend this conference.		
John Turner	Committee member, lay member	Appointed to NIHR Senior investigators award panel	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update

The Chair and a senior member of the Developer's team noted that otherwise, the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of previous meeting**

The minutes of the previous meeting were accepted as a true and accurate record.

### **4. Overview of post-consultation process**

The Chair introduced NICE Senior Technical Analyst George Wood (GW), who outlined the post-consultation process and the objectives of this meeting.

### **5. Discussion on stakeholder comments and review of recommendations**

GW led a discussion on the issues raised during stakeholder consultation with the committee, who revisited and finalised draft recommendations as appropriate.

The committee also revisited and confirmed updated recommendations on insulins with NICE Pharmacist Clinical Adviser Magdalena Watras.

### **6. AOB**

The Chair reminded the group that Day two of the meeting is scheduled to commence at 09:30 the following day, thanked participants and closed the meeting.

## Type 2 Diabetes in adults (medicines update) Committee meeting 14 Day 2

**Date:** 24/10/2025

**Location:** Hybrid, NICE London Office

**Minutes:** Draft

<b>Committee members present:</b>		
Waqaar Shah (Chair)		Present for notes 1 – 5
Chirag Bakhai		Present for notes 1 – 5
Catherine Bewsey		Present for notes 1 – 5
Mimi Chen		Present for notes 1 – 5
Hussain Contractor		Present for notes 1 – 5
Dan Cuthbertson (Topic Adviser)		Present for notes 1 – 5
Anne Dornhorst		Present for notes 1 – 5
Hugh Gallagher		Present for notes 1 – 5
Natasha Jacques		Present for notes 1 – 5
Sallianne Kavanagh		Present for notes 1 – 5
Sharon McCarthy		Present for notes 1 – 5
Soon Song		Present for notes 1 – 5
Annette Swinkels		Present for notes 1 – 5
Dominic Taylor		Present for notes 1 – 5
John Turner		Present for notes 1 – 5

<b>In attendance:</b>		
Sarah Dwyer	Technical Analyst	Present for notes 1 – 5
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 – 5
James Hawkins	Health Economics Adviser	Present for notes 1 – 5
Lina Manounah	Technical Analyst	Present for notes 1 – 5
Sarah Matthews	Technical Analyst	Present for notes 1 – 5
Caroline Mulvihill	Topic Lead	Present for notes 1 – 5
Adam O'Keefe	Project Manager	Present for notes 1 – 5
Muksitur Rahman	Health Economist	Present for notes 1 – 5
Philip Williams	Finance Analyst	Present for notes 1 – 5
George Wood	Senior Technical Analyst	Present for notes 1 – 5

**NICE observers:**

Charlotte Fairclough	Technical Analyst, Centre for Guidelines, NICE
Lesley Owen	Health Economics Adviser, SEA Directorate, NICE

**Apologies:**

Neel Basudev	Committee member
Sithembile Thokozile Chinaire	Committee member
Gosia Wamil	Committee member
Astrid Aregui	Senior Guidance Content Designer, NICE

**1. Welcome, introductions and apologies**

The Chair welcomed the Committee members and attendees to Day two of the fourteenth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, no new interest were declared.

The Chair and a senior member of the Developer's team noted that no previously declared interests would prevent the attendees from fully participating in the meeting.

**3. Discussion on stakeholder comments and review of recommendations**

The committee continued the discussion from the previous day, with NICE Senior Technical Analyst George Wood leading a discussion on the issues raised during stakeholder consultation with the committee, who revisited and finalised draft recommendations as appropriate.

This session included a briefing on the related Indicators workstream by NICE Technical Analyst Charlotte Fairclough.

**4. Discussion of inequalities issues raised by stakeholders**

The Chair introduced NICE Topic Lead, Caroline Mulvihill who led a discussion with the committee on the inequalities issues raised by stakeholders during public

consultation. The committee considered any impact on the draft recommendations.

**5. AOB**

Adam O'Keefe, Project Manager outlined next steps to publication of the guideline update. The Chair then thanked participants for their contributions at this meeting and for during development of the guideline and closed the meeting.